Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Paliperidone - Johnson & Johnson

X
Drug Profile

Paliperidone - Johnson & Johnson

Alternative Names: 9-hydroxyrisperidone; Invega; JNS-007ER; Paliperidone controlled release; Paliperidone ER; Paliperidone ER OROS; R0-76477; RO-76477

Latest Information Update: 01 Jul 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Johnson & Johnson
  • Developer Janssen Pharmaceutical KK; Johnson & Johnson
  • Class 2 ring heterocyclic compounds; Antipsychotics; Fluorobenzenes; Isoxazoles; Piperidines; Pyrimidinones; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 5-HT2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Aggression; Agitation; Schizoaffective disorder; Schizophrenia
  • Discontinued Bipolar disorders; Insomnia; Manic episodes

Most Recent Events

  • 04 Mar 2020 Janssen-Cilag completes the phase III trial for Schizophrenia in Belgium, Bulgaria, Croatia, Denmark, Finland, France, Germany, Greece, Hungary, Israel, Latvia, Lithuania, Netherlands, Poland, Portugal, Russia, Serbia, Spain, Sweden, Switzerland, Turkey and United Kingdom (NCT00460512)
  • 05 Mar 2015 No recent reports on development identified - Phase-III for Schizophrenia (In adolescents) in India, Russia, South Korea and Ukraine (PO)
  • 04 Jun 2014 Registered for Schizophrenia (in adolescents aged 15 years and older) in European Union (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top